Evidence map›Paper›PMID 40667113›Full record

ArticlebioRxiv : the preprint server for biology2025

Genital herpes shedding episodes associate with alterations in the spatial organization and activation of mucosal immune cells.

Finn MacLean, Rachael M Zemek, Adino Tesfahun Tsegaye, Jessica B Graham, Jessica L Swarts, Sarah C Vick, Nicole B Potchen, Irene Cruz Talavera, Lakshmi Warrier, Julien Dubrulle and 15 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Finn MacLeanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Rachael M ZemekVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Adino Tesfahun TsegayeDepartment of Global Health, University of Washington, Seattle, USA.
Jessica B GrahamVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Jessica L SwartsVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Sarah C VickVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Nicole B PotchenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Irene Cruz TalaveraVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Lakshmi WarrierVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Julien DubrulleCellular Imaging Shared Resource, Fred Hutchinson Cancer Center, Seattle, USA.
Lena K SchroederCellular Imaging Shared Resource, Fred Hutchinson Cancer Center, Seattle, USA.
Anna ElzFred Hutch Innovation Lab, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-7718-3015
David SowerbyFred Hutch Innovation Lab, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Ayumi SaitoDepartment of Global Health, University of Washington, Seattle, USA.
Katherine K ThomasDepartment of Global Health, University of Washington, Seattle, USA.
Matthias MackDepartment of Internal Medicine-Nephrology, University Hospital Regensburg, Regensburg, Germany.
Joshua T SchifferVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
R Scott McClellandDepartment of Global Health, University of Washington, Seattle, USA.
Keith R JeromeVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Bhavna H ChohanDepartment of Global Health, University of Washington, Seattle, USA.
Kenneth NgureDepartment of Global Health, University of Washington, Seattle, USA.
Nelly Rwamba MugoDepartment of Global Health, University of Washington, Seattle, USA.
Evan W NewellVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.
Jairam R LingappaDepartment of Global Health, University of Washington, Seattle, USA.
Jennifer M LundVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.ORCID 0000-0003-3284-979X

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Diseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3M
Identification of Novel Mucosal Immune Mechanisms Involved in Protection from HIV-1R01AI131914 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LINGAPPA, JAIRAM RAO, LUND, JENNIFER M · 2017 to 2021
$4.0M
T-cell activation and exhaustion in the HIV-positive female genital tractR01HD114505 · NICHD · UNIVERSITY OF WASHINGTON · PI Jennifer M Lund, Raymond Scott McClelland · 2023 to 2026
$3.9M
Evaluating the relationship of CD101 and UBE2V1 to genital mucosal inflammationR01AI129715 · NIAID · UNIVERSITY OF WASHINGTON · PI LINGAPPA, JAIRAM RAO · 2017 to 2021
$3.6M
Tissue Regulatory T Cells in Mucosal InfectionR01AI141435 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LUND, JENNIFER M · 2019 to 2023
$3.2M
Viral Pathogenesis Training ProgramT32AI083203 · NIAID · UNIVERSITY OF WASHINGTON · PI BLOOM, JESSE D, LAGUNOFF, MICHAEL · 2009 to 2023
$2.7M
Regulatory T cell coordination of the mucosal NK cell response during viral infectionK99AI180649 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Sarah C Vick · 2024 to 2026
$257k
NCI NIH HHS P30 CA015704NIAID NIH HHS K99 AI180649NIAID NIH HHS R01 AI129715NIAID NIH HHS R01 AI131914NIAID NIH HHS R01 AI141435NIAID NIH HHS T32 AI007140NIAID NIH HHS T32 AI007509NIAID NIH HHS T32 AI083203NICHD NIH HHS R01 HD114505
6 · The paper itself

Abstract

Herpes Simplex Virus 2 (HSV-2) infection results in variable rates of local viral shedding in anogenital skin. The impact of episodic viral exposures on immune cells in adjacent mucosal tissues, including the genital tract, is unknown. However, any immune responses at this site could impact protective mucosal immunity, tissue homeostasis, and adverse health outcomes. To investigate the impact of HSV-2 on cervicovaginal tract immunity, we applied flow cytometry, immunofluorescent imaging, analysis of soluble immune factors, and spatial transcriptomics to cervicovaginal tissue and blood samples provided by a total of 232 HSV-2 seropositive and seronegative participants, with genital HSV-2 shedding evaluated at the time of biopsy. This unique dataset was used to define and spatially map immune cell subsets and localized gene expression via spatial transcriptomics. HSV-2 seropositivity alone was associated with minimal differences in cervicovaginal and circulating T cell phenotypes. However, the vaginal mucosa during active HSV-2 shedding was associated with alterations in T cell, macrophage, and dendritic cell localization and gene expression consistent with increased immune surveillance, with immune activating and suppressing signals potentially reinforcing mucosal tissue homeostasis.

Identifiers

PMID40667113
PMCPMC12262732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.